In this cohort, we evaluated the presence of cross-lineage myeloid markers such as CD66c, CD33, CD13 and CD15, some associated with specific molecular abnormalities including NG2 and CD9, and overexpression of B-cell lineage markers in B-ALL cases. The gene discussed is CEACAM6; the disease is acute lymphoblastic leukemia.